These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 1472380)
81. Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Van Regenmortel MH Arch Virol; 2012 Jan; 157(1):1-20. PubMed ID: 22012269 [TBL] [Abstract][Full Text] [Related]
82. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. Bautz DJ; Preston GA; Lionaki S; Hewins P; Wolberg AS; Yang JJ; Hogan SL; Chin H; Moll S; Jennette JC; Falk RJ J Am Soc Nephrol; 2008 Dec; 19(12):2421-9. PubMed ID: 18701607 [TBL] [Abstract][Full Text] [Related]
83. ANCA patients have T cells responsive to complementary PR-3 antigen. Yang J; Bautz DJ; Lionaki S; Hogan SL; Chin H; Tisch RM; Schmitz JL; Pressler BM; Jennette JC; Falk RJ; Preston GA Kidney Int; 2008 Nov; 74(9):1159-69. PubMed ID: 18596726 [TBL] [Abstract][Full Text] [Related]
84. Induction of human immunodeficiency virus (HIV-1) envelope specific cell-mediated immunity by a non-homologous synthetic peptide. Achour A; Biquard JM; Krsmanovic V; M'bika JP; Ficheux D; Sikorska M; Cozzone AJ PLoS One; 2007 Nov; 2(11):e1214. PubMed ID: 18043730 [TBL] [Abstract][Full Text] [Related]
85. Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease. Pendergraft WF; Pressler BM; Jennette JC; Falk RJ; Preston GA J Mol Med (Berl); 2005 Jan; 83(1):12-25. PubMed ID: 15592920 [TBL] [Abstract][Full Text] [Related]
86. Regulation of CAT protein by ribozyme and antisense mRNA in transgenic mice. Sokol DL; Passey RJ; MacKinlay AG; Murray JD Transgenic Res; 1998 Jan; 7(1):41-50. PubMed ID: 9556913 [TBL] [Abstract][Full Text] [Related]
88. Sense in antisense? Forsdyke DR J Mol Evol; 1995 Nov; 41(5):582-6. PubMed ID: 7490772 [TBL] [Abstract][Full Text] [Related]
89. Genetic coding algorithm for sense and antisense peptide interactions. Štambuk N; Konjevoda P; Turčić P; Kövér K; Kujundžić RN; Manojlović Z; Gabričević M Biosystems; 2018 Feb; 164():199-216. PubMed ID: 29107641 [TBL] [Abstract][Full Text] [Related]
90. Making sense from antisense: a review of experimental data and developing ideas on sense--antisense peptide recognition. Tropsha A; Kizer JS; Chaiken IM J Mol Recognit; 1992 Jun; 5(2):43-54. PubMed ID: 1472380 [TBL] [Abstract][Full Text] [Related]
91. The possible role of sense and antisense peptide interactions in the generation and maintenance of the tertiary structure of a protein. Okada H Anticancer Res; 1998; 18(5D):3927-30. PubMed ID: 9854505 [TBL] [Abstract][Full Text] [Related]
92. Interactions and uses of antisense peptides in affinity technology. Chaiken I J Chromatogr; 1992 Apr; 597(1-2):29-36. PubMed ID: 1517330 [TBL] [Abstract][Full Text] [Related]
93. Making sense of antisense and interference. Morrow T Manag Care; 2003 Nov; 12(11):62-3. PubMed ID: 14666589 [No Abstract] [Full Text] [Related]
94. Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain. Hou T; Zhang W; Case DA; Wang W J Mol Biol; 2008 Feb; 376(4):1201-14. PubMed ID: 18206907 [TBL] [Abstract][Full Text] [Related]